Loading clinical trials...

COMPLETEDPHASE2

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342•Bayer

View on ClinicalTrials.gov

Summary

The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.

Detailed Description

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.

Eligibility

Age

45 - 65 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•\- Postmenopausal women 45 - 65 years old with prehypertension

Exclusion Criteria

•\- Hormone therapy (estrogen/progestin)

Locations (9)

Greenbrae, California, United States

San Diego, California, United States

Daytona Beach, Florida, United States

Miami, Florida, United States

Paw Paw, Michigan, United States

Las Vegas, Nevada, United States

Philadelphia, Pennsylvania, United States

Columbia, South Carolina, United States

Arlington, Virginia, United States

Key Dates

Start Date

January 1, 2007

Primary Completion Date

September 1, 2008

Completion Date

September 1, 2008

Last Updated

June 2, 2015

Enrollment

ACTUAL participants

Conditions

PostmenopauseHypertensionPre-Hypertension

Interventions

Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)

DRUG

Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)

DRUG

SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)

DRUG

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGPHASE2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 2, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets